CJC-1295 and Ipamorelin are often studied together in the research-peptide space. This article explains what each compound does, why researchers pair them, what preclinical evidence has reported, and where they stand regulatorily in 2026. Nothing here is medical advice; neither compound is FDA-approved for therapeutic use.
CJC-1295 is a synthetic 30-amino-acid analog of human growth-hormone-releasing hormone (GHRH). It was designed to have a longer duration of action than native GHRH, making it suitable for research into pituitary-directed GH secretion. The compound is typically studied in two forms: "No DAC" (without drug affinity complex) for shorter-duration studies, and "DAC" (with an albumin-binding domain) for extended half-life research.
Ipamorelin is a selective ghrelin-mimetic — a compound that activates the ghrelin receptor (GHSR-1a) but with high selectivity, meaning it avoids off-target effects on other hormone receptors. Unlike some secretagogues, Ipamorelin does not significantly stimulate cortisol or prolactin, a feature that makes it attractive for research into GH regulation without endocrine side effects.
The somatotropic axis — the system that controls growth hormone (GH) and its downstream effector insulin-like growth factor 1 (IGF-1) — involves two primary stimulatory signals:
CJC-1295 mimics the first signal; Ipamorelin mimics the second. Preclinical research has shown that combining these two mechanisms produces a synergistic GH response — larger GH pulses and higher IGF-1 levels than either compound alone. This synergy makes the combination an important model for studying coordinated endocrine regulation in the lab.
Published studies on the CJC-1295/Ipamorelin combination are limited to animal and cell-based experiments. The most consistent findings are:
Both compounds remain unapproved research chemicals. Individual component pharmacology is established in human trials conducted decades ago, but the FDA has not approved either for therapeutic use. Additionally, both CJC-1295 and Ipamorelin are included on the 2026 WADA Prohibited List as growth-hormone-releasing factors, meaning they are restricted in competition settings.
Neither compound appears on the FDA's current 503A or 503B bulk-substances lists, meaning they cannot be compounded legally through U.S. pharmacies for human use. They remain accessible exclusively as research reagents for laboratory study.
We supply CJC-1295 (No DAC) and Ipamorelin individually to researchers — each HPLC-tested to 99% purity, with certificates of analysis on every batch, shipped from the USA, strictly for in-vitro laboratory use:
View CJC-1295 & Ipamorelin (p011) Browse all research compounds
Universe Peptide publishes research-focused education for the scientific community. Products are for laboratory research only. See more in our News & research updates.